Janssen’s Esketamine Needs Better Defined REMS, US FDA Panel Says

Advisory committee overwhelmingly endorses approval for patients with treatment-resistant depression but says proposed Risk Evaluation and Mitigation Strategy needs refinement, including clarifying the types of facilities where the drug will be administered.

FDA Advisory Committee Feature image

A US FDA advisory committee backed the approval of Janssen R&D LLC’s depression drug esketamine but said the parameters of a proposed Risk Evaluation and Mitigation Strategy (REMS) need to be better defined, particularly as to the types of facilities where the drug will be administered.

The Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee on Feb. 12 strongly endorsed the efficacy,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers